2025 Silent Capital Report now available. Where family offices and LPs are actually deploying. [Download for free →]
About usSign in
Status
ACTIVE
Global HQ
Prague, Czech Republic
Countries of investment
  • Czech Republic
  • Germany
Investment stages
  • Pre-Seed
  • Seed
  • Series A
Industries
  • Deep Tech
  • AI
  • Robotics
  • Biotechnology
  • Life Sciences
  • MedTech
  • Climate Tech
  • Quantum Computing
About
IP Lab Ventures is a Prague-based venture firm investing in university and research spin-offs. Its Fund I is targeting $58M, with about $31M committed by the EIF. Their investments are concentrated in the Czech Republic, with a portfolio project in Germany, and the firm covers the wider Central and Eastern European region in its mandate. The fund is aimed at deep tech companies that originate in academic labs.
Min check size
$220K
Max check size
$2.7M
Fund size
NPS

Investment Thesis

IP Lab Ventures is an early-stage venture firm commercializing science from universities and research institutes, from pre-seed to Series A. Their core thesis is that technology transfer is an underused source of deep tech companies in the Czech Republic and wider Central and Eastern Europe, and that spin-offs need both early capital and commercialization support. What makes IP Lab unique is that its Fund I is Czechia’s first technology transfer fund, backed by about $31M from the EIF through the Czech recovery fund of funds.
Lead investor
Co Invest
Number of exits
Preferred contact method

Manager's Experience

Led by three General Partners, Filip Fingl (platform and venture leadership), Jiří Navrátil (science, IP and tech transfer) and Andrew Hladký (operations, finance and transactions), with Jan Krabec as Legal Counsel. The team incubates and co-founds companies from university and research IP, including Atomiver, MendelFOLD, Preagon Biotech, GWN, AMADTEUS and Biorea, ahead of a formal fund close. Builds deep tech and life science companies out of IP.

IP Lab Ventures Contacts Information

Primary contact

Secondary contact

Team

Filip Fingl - General Partner (Platform & Venture Leadership)

Jiří Navrátil - General Partner (Science

IP & Tech Transfer)

Andrew Hladký - General Partner (Operations

Finance & Transactions)

Jan Krabec - Legal Counsel (Fund & Transaction Structuring)

Portfolio

Atomiver

MendelFOLD

Preagon Biotech

GWN

AMADTEUS

Biorea

Fund number
Year Founded
Vintage Year
Net Internal Rate of Return
Investment Multiple
Capital Allocation
Management Fee
Carried Interest
AUM
Follow-on Investments
Graduation Rate
Write-Off Ratio
Last profile update timestamp